GSK-256066 Completed Phase 2 Trials for Seasonal Allergic Rhinitis Treatment

Back to GSK-256066
IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00377728
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
NCT00430157
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
NCT00612820
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
NCT00464568
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis